Free Trial

Biogen (BIIB) Stock Price, News & Analysis

Biogen logo
$142.78 +2.84 (+2.03%)
As of 11:07 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Biogen Stock (NASDAQ:BIIB)

Key Stats

Today's Range
$139.96
$144.20
50-Day Range
$122.68
$141.62
52-Week Range
$110.04
$204.18
Volume
331,416 shs
Average Volume
1.55 million shs
Market Capitalization
$20.93 billion
P/E Ratio
13.58
Dividend Yield
N/A
Price Target
$185.74
Consensus Rating
Hold

Company Overview

Biogen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
97th Percentile Overall Score

BIIB MarketRank™: 

Biogen scored higher than 97% of companies evaluated by MarketBeat, and ranked 47th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biogen has received a consensus rating of Hold. The company's average rating score is 2.34, and is based on 11 buy ratings, 21 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Biogen has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Biogen's stock forecast and price target.
  • Earnings Growth

    Earnings for Biogen are expected to grow by 4.30% in the coming year, from $15.83 to $16.51 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biogen is 13.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 277.97.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biogen is 13.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.77.

  • Price to Earnings Growth Ratio

    Biogen has a PEG Ratio of 1.12. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Biogen has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Biogen's valuation and earnings.
  • Percentage of Shares Shorted

    2.84% of the float of Biogen has been sold short.
  • Short Interest Ratio / Days to Cover

    Biogen has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biogen has recently increased by 5.05%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Biogen does not currently pay a dividend.

  • Dividend Growth

    Biogen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.84% of the float of Biogen has been sold short.
  • Short Interest Ratio / Days to Cover

    Biogen has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biogen has recently increased by 5.05%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Biogen has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 45 news articles for Biogen this week, compared to 28 articles on an average week.
  • Search Interest

    44 people have searched for BIIB on MarketBeat in the last 30 days. This is an increase of 132% compared to the previous 30 days.
  • MarketBeat Follows

    Only 10 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Biogen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $369,150.00 in company stock.

  • Percentage Held by Insiders

    Only 0.18% of the stock of Biogen is held by insiders.

  • Percentage Held by Institutions

    87.93% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Biogen's insider trading history.
Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIIB Stock News Headlines

5BIIB : Beyond The Numbers: 10 Analysts Discuss Biogen Stock
Washington prepares for war
While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.tc pixel
Biogen (BIIB) Stock Trades Down, Here Is Why
See More Headlines

BIIB Stock Analysis - Frequently Asked Questions

Biogen's stock was trading at $152.92 on January 1st, 2025. Since then, BIIB shares have decreased by 8.3% and is now trading at $140.2920.

Biogen Inc. (NASDAQ:BIIB) released its quarterly earnings data on Thursday, July, 31st. The biotechnology company reported $5.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.93 by $1.54. The business's revenue for the quarter was up 7.3% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of Biogen: Nightstar Therapeutics plc, Convergence Pharmaceuticals, TYSABRI, Stromedix Inc., Panima Pharmaceuticals AG, Syntonix Pharmaceuticals Inc., Fumapharm, and others.

Top institutional investors of Biogen include Vanguard Group Inc. (11.79%), Primecap Management Co. CA (10.78%), State Street Corp (5.09%) and Geode Capital Management LLC (2.67%). Insiders that own company stock include Susan H Alexander, Eric K Rowinsky, Stephen A Sherwin, Stephen A Sherwin, Stephen A Sherwin, Ginger Gregory, Rachid Izzar and Priya Singhal.
View institutional ownership trends
.

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biogen investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Broadcom (AVGO) and Intel (INTC).

Company Calendar

Last Earnings
7/31/2025
Today
9/05/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BIIB
CIK
875045
Employees
7,605
Year Founded
1978

Price Target and Rating

High Price Target
$292.00
Low Price Target
$118.00
Potential Upside/Downside
+32.7%
Consensus Rating
Hold
Rating Score (0-4)
2.34
Research Coverage
32 Analysts

Profitability

EPS (Trailing Twelve Months)
$10.46
Trailing P/E Ratio
13.38
Forward P/E Ratio
8.84
P/E Growth
1.12
Net Income
$1.63 billion
Net Margins
15.31%
Pretax Margin
17.98%
Return on Equity
13.85%
Return on Assets
8.32%

Debt

Debt-to-Equity Ratio
0.36
Current Ratio
2.50
Quick Ratio
1.79

Sales & Book Value

Annual Sales
$9.68 billion
Price / Sales
2.12
Cash Flow
$22.83 per share
Price / Cash Flow
6.13
Book Value
$114.71 per share
Price / Book
1.22

Miscellaneous

Outstanding Shares
146,620,000
Free Float
146,351,000
Market Cap
$20.52 billion
Optionable
Optionable
Beta
0.11

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:BIIB) was last updated on 9/5/2025 by MarketBeat.com Staff
From Our Partners